References - Cardiovascular Protocol

1.  Calder PC. "n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases."  Am J Clin Nutr. 2006 Jun;83(6 Suppl):1505S-1519S.

2. Thies F, Miles EA, Nebe-von-Caron G, Powell JR, Hurst TL, Newsholme EA, Calder PC.  "Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults"  Lipids. 2001 Nov;36(11):1183-93.

3. Jiang Q, Wong J, Fyrst H, Saba JD, Ames BN. "gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis."  Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17825-30.

4. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN.  "Gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications."  Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3217-22.

5. Kendler BS.  "Supplemental conditionally essential nutrients in cardiovascular disease therapy."  J Cardiovasc Nurs. 2006 Jan-Feb;21(1):9-16.

6. Rosenfeldt F, Hilton D, Pepe S, Krum H.  "Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure."  Biofactors. 2003;18(1-4):91-100.

7. Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, Inazu A, Koizumi J, Kobayashi J.  "Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients."  J Atheroscler Thromb. 2005;12(2):111-9.

8. Devaraj S, Vega-Lopez S, Kaul N, Schonlau F, Rohdewald P, Jialal I. "Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile." Lipids. 2002 Oct;37(10):931-4.

9. Belcaro G, Cesarone MR, Ricci A, Cornelli U, Rodhewald P, Ledda A, Di Renzo A, Stuard S, Cacchio M, Vinciguerra G, Gizzi G, Pellegrini L, Dugall M, Fano F. "Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol."  Clin Appl Thromb Hemost. 2006 Oct;12(4):440-4.

10. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, Gizzi G, Ippolito E, Fano F, Dugall M, Acerbi G, Cacchio M, Di Renzo A, Hosoi M, Stuard S, Corsi M. "Rapid relief of signs/symptoms in chronic venous microangiopathy with pycnogenol: a prospective, controlled study."  Angiology. 2006 Oct-Nov;57(5):569-76.

11. Riccioni C, Sarcinella R, Izzo A, Palermo G, Liguori M.  "[Effectiveness of Troxerutin in association with Pycnogenol in the pharmacological treatment of venous insufficiency]" Minerva Cardioangiol. 2004 Feb;52(1):43-8. Italian.

12. Tixier JM, Godeau G, Robert AM, Hornebeck W. "Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases." Biochem Pharmacol. 1984 Dec 15;33(24):3933-9.

13. Grimm T, Schafer A, Hogger P. "Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol)."  Free Radic Biol Med. 2004 Mar 15;36(6):811-22.

14. Schafer A, Hogger P. "Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol) effectively inhibit alpha-glucosidase."  Diabetes Res Clin Pra